Author: Ravi Shankar

More than US$800,000 in additional recurring cash costs eliminated since July 1, 2026, through tech delivery, AI supported workflows and operating discipline

Highlights

• Over US$2.51 million in total annualized cash operating cost reductions now implemented
• Over US$800,000 of additional annualized recurring cash costs eliminated since July 1, 2026
• Cumulative annualized cash operating cost reductions increased by 47.2% in less than three months
• New reductions comprise approximately US$445,000 in staff costs, US$181,000 in taxes and benefits, US$116,000 in premises costs and US$64,000 in technology subscriptions and cloud storage
• Technology delivery and AI supported workflows are enabling MMA.INC to streamline operations and operate with a leaner recurring cost base
• All savings result from completed actions embedded in the Company’s operating model
• Lower recurring cash outflows are expected to strengthen operating leverage, extend runway and support the Company’s path toward positive adjusted EBITDA

New York, NY, Sept. 29, 2026 (GLOBE NEWSWIRE) — Mixed Martial Arts Group Limited (NYSE American: MMA) (“MMA” or the “Company”), doing business as MMA.INC, today announced more than US$800,000 in additional annualized cash operating cost reductions, increasing total annualized cash operating cost reductions to over US$2.51 million.

The new reductions were implemented between July 1 and September 28, 2026 and represent a 47.2% increase from approximately US$1.71 million of annualized cash operating cost reductions reported as of June 30, 2026.

The additional savings comprise approximately:

• US$445,000 in staff costs;
• US$181,000 in associated taxes and benefits;
• US$116,000 in premises costs; and
• US$64,000 in technology subscriptions and cloud storage.

Each announced reduction arises from a completed action and represents recurring cash expenditure that management believes is no longer required by the business.

Technology and AI Support Operating Leverage

MMA.INC’s technology delivery program and expanded use of AI supported workflows are enabling the Company to simplify processes, automate manual activity, consolidate infrastructure and support a leaner operating structure.

These actions delivered over US$625,000 in additional workforce related annualized cash cost reductions and over US$180,000 in technology and operating infrastructure annualized cash cost reductions during the period.

The Company believes its technology investment is strengthening MMA.INC’s product platform while reducing the recurring cash cost required to operate the business.

Nick Langton, Founder and Chief Executive Officer of MMA.INC, said:

“Since June 30, we have increased MMA.INC’s annualized cash operating cost reductions from approximately US$1.71 million to approximately US$2.51 million. That 47.2% increase reflects the pace and discipline with which we are reshaping the business.

“Technology delivery, automation and AI supported workflows are translating directly into lower recurring cash costs. We are simplifying how MMA.INC operates, removing expenditure the business no longer requires and building a more scalable operating model.

“These are completed actions, not future targets. We have now removed over US$2.51 million of annualized recurring cash expenditure from the business, strengthening operating leverage, extending runway and supporting our path toward profitability.”

MMA.INC intends to continue pursuing disciplined efficiencies while protecting its core revenue-generating capabilities and strategic priorities. Positive adjusted EBITDA is an operating objective, not a forecast, and the Company is not providing a quantitative target or fixed timetable.

Basis of Annualized Cash Operating Cost Reduction Measure

The annualized cash operating cost reduction of approximately US$2.51 million represents management’s estimate, as of September 28, 2026, of recurring annual cash expenditure eliminated through actions completed between January 1, 2025 and September 28, 2026. The figure is intended to describe annualized recurring cash cost reductions from completed actions and should not be read as a forecast of future profitability, cash flow or financial performance.

The measure was calculated by annualizing each identified cash cost at the rate applying immediately before its elimination. It includes payroll, taxes and benefits, premises, hosting, insurance, technology subscriptions, cloud storage and costs eliminated through the deprecation of selected Hype functionality.

The measure excludes share-based payments, depreciation, amortization and other non-cash expenses.

About Mixed Martial Arts Group Limited

Mixed Martial Arts Group Limited (NYSE American: MMA), doing business as MMA.INC, is building the participation and technology platform for the global martial arts and combat sports industry, connecting practitioners, gyms, coaches, content, commerce and payments.

As of July 2026, MMA.INC’s platform assets included 5 million+ social media followers, 680,000 user profiles, 107,694 registered student profiles, 27,651 monthly active users and 15,326 published gym profiles, including 996 verified and 389 paying academies. The platform also recorded approximately 80,000 monthly check-ins and an annualized payments run rate of approximately US$21 million based on May 2026 processing volumes.

• A Connected Participation Platform: MMA.INC brings together gym software, payments, training, community, content and commerce through assets including BJJLink, TrainAlta, Hype and MixedMartialArts.com.
• A Growing Participation Network: Over the prior 18 months, registered student profiles increased approximately 101%, monthly active users approximately 89% and paying academies approximately 260%.
• Built to Aggregate the Sector: MMA.INC’s strategy is to connect the fragmented martial arts participation economy through a unified digital identity and ecosystem designed to deepen engagement and expand monetization across software, payments, programs, memberships, partnerships and commerce.

For more information, visit www.mma.inc

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Sections 27A of the Securities Act of 1933, as amended, and 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than statements of historical fact and may be identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “target,” “objective,” “may,” “will,” “could,” “should,” “continue,” “potential” and similar expressions. Forward-looking statements in this release include, without limitation, statements regarding the expected amount, timing and durability of the Company’s annualized cash operating cost reductions; the Company’s ability to maintain a lower recurring cost base; the anticipated benefits of technology delivery, automation and AI-supported workflows; the expected effects of the cost reductions on operating leverage, cash usage, cash runway, margins, adjusted EBITDA, profitability and financial condition; the scalability of the Company’s operating model; and the Company’s intention to identify and implement further efficiencies without compromising its revenue-generating capabilities, product delivery or strategic priorities. These forward-looking statements are based on management’s current expectations, estimates, assumptions and information available as of the date of this release. Actual results could differ materially due to risks and uncertainties including, among others: the risk that estimated or annualized savings are not realized, maintained or reflected in future operating results at the amounts or within the periods anticipated; the possibility that savings are offset by restructuring or transition costs, wage or supplier inflation, replacement expenditure, additional hiring, technology investment or other operating requirements; the accuracy and completeness of the data and assumptions used to calculate and annualize the cost reductions; the risk that workforce reductions, organizational changes or infrastructure consolidation disrupt operations, internal controls, product development, customer service or revenue growth; the Company’s ability to successfully implement and maintain technology, automation and AI-supported processes; cybersecurity, data protection, privacy, reliability and other risks arising from increased reliance on technology and AI; the Company’s ability to retain key personnel and maintain relationships with customers, gyms, academies, partners and suppliers; the Company’s ability to grow revenue, improve margins and manage its liquidity and capital requirements; general economic, market and regulatory conditions; and the Company’s ability to access additional capital when required. Additional risks and uncertainties include those described under “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in subsequent reports on Form 6-K filed with or furnished to the U.S. Securities and Exchange Commission. The annualized cost-reduction figures presented in this release are management estimates based on the recurring cash costs applying immediately before the relevant costs were eliminated. They are not forecasts of future profitability, cash flow or financial performance. Cost reductions alone may not result in positive adjusted EBITDA or profitability, and there can be no assurance that the Company will achieve those objectives within any particular period or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them as a result of new information, future events or otherwise, except as required by applicable law.

Media Contacts

Mixed Martial Arts Group Limited
E: andrew@mma.inc

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading EV charging operator, is pleased to announce that it has entered into a definitive agreement (the “Definitive Agreement”), signed September 28, 2026, to acquire 100% of the equity interests of REVS Charging LLC (“REVS”), a Texas-based provider of electric vehicle charging solutions (the “Transaction”). The Transaction is expected to close on October 1, 2026, subject to customary closing conditions and receipt of the requisite TSX Venture Exchange (the “TSXV”) approval.

The Transaction marks an important step in Hypercharge’s North American growth strategy by establishing on the ground operations in the United States which will complement the Company’s existing charging network in 14 states today, expanding the Company’s portfolio of owned and operated charging infrastructure, and increasing its recurring services and subscription revenue.

Transaction Structure and Consideration

The Transaction values REVS on an enterprise basis up to US$4,750,000 (the “Purchase Price”), subject to customary closing adjustments for working capital, indebtedness and transaction expenses. The Purchase Price is payable as follows:

• Closing share consideration: US$3,000,000 (63% of the Purchase Price), payable in common shares of Hypercharge (the “Common Shares”) at closing, to be issued at a deemed price of C$0.23 per Common Share and subject to a six-month lock-up;
• Closing cash consideration: US$500,000 (11% of the Purchase Price), payable in cash at closing;
• Deferred consideration: up to US$1,250,000 (26% of the Purchase Price), payable in Common Shares over three annual tranches contingent on REVS meeting gross profit performance milestones of US$850,000 in year 1, US$1,200,000 in year 2, and US$2,000,000 in year 3. The Common Shares issuable as deferred consideration will be priced based on the 20-day volume-weighted average trading price of the Common Shares as of the applicable issuance date, subject to a floor price of C$0.23 per Common Share and a ceiling price of C$0.50 per Common Share.

As part of the Transaction, the Company provided REVS with an interim secured loan of US$200,000 (the “Loan”) during the exclusivity period under the letter of intent, signed May 27, 2026, to support REVS’ ongoing operations. Upon closing of the Transaction, the Loan, together with certain capital expenditure advances made to REVS, and accrued interest shall be extinguished and treated as an equity investment by the Company.

No finder’s fee are payable and there are no relationships with any non-arm’s length parties pursuant to the Transaction or the Loan.

Strategic and Investment Highlights

• Establishes a U.S. operating platform: REVS provides Hypercharge with an established U.S. business, customer relationships, local operating capabilities, and a foundation for further expansion across North America.
• Expands recurring revenue: REVS generates more than C$1 million in annual charging and services revenue, at a gross margin of >45%, increasing Hypercharge’s recurring revenue base.
• Accelerates the owned-and-operated strategy: REVS brings a portfolio of more than 500 owned Level 2 charging ports, together with approximately 700 additional customer-owned charging ports deployed across the United States, bringing Hypercharge’s network to over 10,000 sold or owned charging ports across North America.
• Increases flexibility in the U.S. market: An established U.S. operation will allow Hypercharge to serve customers, build local partnerships, and develop sourcing and supplier relationships with greater flexibility amid changing trade policies and tariffs.
• Aligns consideration with future performance: The Transaction combines limited upfront cash consideration, Common Shares issued at a deemed price of C$0.23 per Common Share, and deferred consideration tied to REVS achieving future gross profit milestones.
• Supports a broader M&A strategy: Hypercharge will continue to pursue additional acquisition opportunities that could expand its geographic presence, recurring revenue, and owned-and-operated charging portfolio across North America.

In connection with closing, David Aaronson, Founder and CEO of REVS and its affiliated operating businesses, will join the Company as President of Hypercharge Networks Inc., Hypercharge’s U.S. subsidiary.

“This is an important step in Hypercharge’s growth strategy. REVS gives Hypercharge an established operating business in the United States. It also expands our recurring revenue base and accelerates our shift toward owning and operating EV charging infrastructure.

“As a Canadian company, we’ve had to navigate changing trade policies and tariffs. Having operations on the ground in the U.S. gives us more flexibility in how we serve customers, build partnerships, and source equipment. By combining REVS’ experience owning and operating charging infrastructure with Hypercharge’s technology, purchasing power, and operational capabilities, we have a strong foundation to grow across the U.S. market.

“We’ve been very deliberate about where we invest our capital and how we grow the business. The structure of this transaction reflects that approach, with limited upfront cash, Common Shares issued at a deemed price of C$0.23 per Common Share, and additional consideration tied to REVS achieving future gross profit milestones. REVS’ commitment to preferring Common Shares over upfront cash demonstrates their confidence in the value of Hypercharge and what we can build together. By taking a significant portion of the purchase price in Common Shares, REVS shareholders will participate in the future of the combined business alongside our existing shareholders.

“The Transaction builds on the acquisition of Eddie, which we completed earlier this year. We intend to look for other acquisition opportunities that expand our geographic presence, grow our recurring revenue, and strengthen our ability to own and operate charging infrastructure across North America. We’re excited to welcome David Aaronson and the REVS team to Hypercharge and look forward to building on what they’ve established,” said David Bibby, President and CEO of Hypercharge.

“This transaction with Hypercharge marks an important milestone for REVS. By combining our U.S. operating experience and owned charging portfolio with Hypercharge’s technology, purchasing power, and operational capabilities, we believe we can accelerate growth and build a stronger North American charging platform,” said David Aaronson, Founder and CEO of REVS.

Existing REVS customers can expect uninterrupted service. During the transition period, Hypercharge and REVS will work together to support a seamless customer experience and will share updates with customers as the integration advances.

FMI Capital Advisory Inc. (FMICA) acted as the exclusive financial advisor to Hypercharge Networks Corp. in its acquisition of REVS Charging LLC.

The parties expect the Transaction to close October 1, 2026, subject to the satisfaction of customary closing conditions and receiving the requisite TSX-V approvals.

Marketing Update

Hypercharge has engaged Toronto-based Anchor Point Advisory Services Inc. (“Anchor Point”) to provide investor relations advisory services. Anchor Point will assist the Company with its investor relations strategy, communications with the investment community and investor meetings. Under the terms of the engagement agreement (the “Agreement”), the Company will pay Anchor Point CAD$3,500 per month for an initial term of six (6) months, continuing thereafter on a month-to-month basis unless terminated. In addition, and subject to the approval of the Company’s board of directors, the Company will grant Anchor Point 200,000 incentive stock options exercisable at a price of $0.09 per share for a period of 3 years, vesting in equal tranches every six months over a two-year period. Anchor Point and its principals currently hold no securities of the Company and have no present intention to acquire securities of the Company and are arm’s length to the Company. The Agreement is subject to the acceptance of the TSX Venture Exchange.

About REVS
Refuel Electric Vehicle Solutions (REVS) is a full-service electric vehicle (EV) charging company providing turnkey Level 2 charging solutions for multifamily, condominium, hospitality, and commercial properties across the United States. With expertise in commercial real estate and EV infrastructure, REVS helps property owners, managers, and developers plan, finance, install, operate, and manage charging stations, including deployment opportunities with no upfront capital investment. Learn more: https://www.refuelevs.com/.

About Hypercharge
Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) is a leading provider of smart electric vehicle (EV) charging solutions for residential and commercial buildings, fleet operations, and other rapidly growing sectors. Driven by its mission to accelerate EV adoption and enable the shift towards a carbon neutral economy, Hypercharge is committed to offering seamless, simple solutions, including industry-leading hardware, innovative and integrated software, and comprehensive services, backed by a robust network of public and private charging stations. Learn more: https://hypercharge.com/.

About FMI Capital Advisory Inc.
FMI Capital Advisory is a leading Toronto-based independent investment bank focused on corporate finance and providing capital markets advisory services.
www.fmicap.com | +1 (416) 777-7300

On behalf of the Company,
Hypercharge Networks Corp.
David Bibby, President & CEO

Contact
Media & Investor Relations:
Kyle Kingsnorth, Head of Marketing
kyle.kingsnorth@hypercharge.com | +1 (888) 320-2633

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Statements in this news release that are not statements of historical fact may be forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements regarding the expected closing date and completion of the Transaction; receipt of TSXV approval and satisfaction of closing conditions; the expected appointment and role of David Aaronson; the anticipated benefits of the Transaction, including the establishment and expansion of Hypercharge’s U.S. operations, growth in recurring revenue and ports sold, owned, or deployed, operating efficiencies, local sourcing and partnerships, and expansion of the owned-and-operated charging model; the integration of REVS; REVS’ future gross profit performance and any related deferred consideration; and Hypercharge’s plans to pursue additional acquisitions and expand across North America. Forward-looking statements are often identified by terms such as “may”, “could”, “should”, “anticipate”, “will”, “estimates”, “believes”, “intends”, “expects”, “plans”, and similar expressions. Forward-looking statements are inherently uncertain and are based on management’s current expectations, estimates, assumptions, and beliefs, which may prove to be incorrect. Actual results may differ materially due to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, among others: the risk that the Transaction does not close on the anticipated timeline or at all, including as a result of a failure to obtain TSXV acceptance or satisfy closing conditions; risks relating to the integration of REVS and the retention of its key personnel and customers; the risk that REVS does not achieve the gross profit milestones; fluctuations in foreign exchange rates; changes in U.S. and Canadian trade policies, tariffs, and government incentives for EV charging infrastructure; dilution to existing shareholders resulting from the issuance of Common Shares; and the other risk factors described in the Company’s continuous disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements.

The forward-looking statements contained in this news release are made as of the date of this news release, and are expressly qualified by the foregoing cautionary statement. Except as expressly required by applicable securities law, the Company undertakes no obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

53,000-square-foot facility is supporting expanded production, system integration and scaling of Canadian uncrewed and autonomous systems for domestic and allied markets

MIRABEL, Québec, Sept. 29, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a global aerospace and defence company, today marked the official opening of its 53,000-square-foot manufacturing and systems integration facility in Mirabel, Québec, representing a significant expansion of the Company’s Canadian production capacity and its ability to scale advanced uncrewed and autonomous systems.

Operational since earlier this year, the Mirabel facility is already supporting Volatus’ expanding manufacturing activities.  Production of drone docking stations is underway, with the site also supporting the integration and production of Volatus’ V-Series aircraft and other advanced autonomous systems.

Located within the aerospace cluster surrounding Montréal-Mirabel International Airport, the facility brings manufacturing, systems integration and technology advancement together in a Canadian production environment. The investment is designed to position Volatus to respond to growing requirements across defence, public safety, industrial and commercial markets in Canada and allied countries.

“Mirabel is an important part of the next stage of Volatus’ growth,” said Glen Lynch, CEO of Volatus. “As demand for autonomous systems grows, our ability to manufacture, integrate and deliver at scale becomes increasingly important. This facility gives us the infrastructure to expand production, accelerate the commercialization of Canadian technologies and serve customers in Canada and allied markets.”

The official opening brought together government, industry, investment and community leaders and included remarks, a ribbon-cutting ceremony and a tour of the facility.

Joining Lynch for the ceremony were MP Carlos Leitão, Parliamentary Secretary to the Minister of Industry; MP Madeleine Chenette, Isabelle Hudon, President and Chief Executive Officer of BDC; Roxanne Therrien, Mayor of Mirabel; and Yves Beauchamp, President and Chief Executive Officer of Aéroports de Montréal, along with representatives from Canada’s aerospace, defence, investment and business communities.

“Building sovereign capability requires more than developing great technology,” added Lynch. “It requires the ability to manufacture, integrate, test and support that technology here in Canada. Mirabel strengthens that capability and provides a platform from which we can continue to scale production and pursue opportunities across Canada, NATO and allied markets.”

The grand opening represents another milestone in Volatus’ strategy to translate its technology portfolio, operational expertise and growing manufacturing capabilities into scalable solutions for customers in Canada and internationally.

About Volatus Aerospace
Volatus Aerospace is a Canadian-headquartered global aerospace and defence company delivering intelligence and cargo solutions through piloted and remotely piloted aircraft systems. With operations, training programs and strategic partnerships spanning multiple continents, Volatus supports government, defence and commercial customers worldwide. The Company leverages advanced technologies, remote operations expertise and aviation experience to solve complex operational challenges in demanding environments.

Forward-Looking Information
This news release contains statements that constitute “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities, events, developments and operating performance. Often, but not always, forward-looking information and forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “seeks”, “strategy” or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking information includes information regarding: (i) the business plans, business outlook and expectations of the Company; and (ii) expectations for other economic, business, and/or competitive factors.

Forward-looking information is based on currently available competitive, financial, and economic data and operating plans, strategies, or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to the Company, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement. 

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information and forward-looking statements reflect the Company’s current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include but are not limited to: the commercialization of drone flights beyond visual line of sight and potential benefits to the Company; and meeting the continued listing requirements of the TSX. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. The forward-looking information contained herein is made as of the date of this news release and, other than as required by law, the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

For additional information, please contact:
Volatus Aerospace Inc. 
Rob Walker, Chief Commercial Officer 
+1-833-865-2887 
investorrelations@volatusaerospace.com 
https://volatusaerospace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c2cc4b8-0cb8-47bd-9059-553570c53f4c

To Nasdaq Copenhagen A/S	25. September 2026
	Announcement no. 82/2026

Correction: The end dates of the stated interest rate periods in the published company announcement were incorrectly specified. The interest rates apply until and including the last day of the respective interest rate periods (the end of the relevant calendar quarter), not the first day of the subsequent calendar quarter. All other information remains unchanged.

Fixing of Coupon Interest Rate

Interest rate for Jyske Realkredit’s:

Series BRF454BOA 38 with ISIN DK0009361628 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154B 38 with ISIN DK0009361701 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154E 41 with ISIN DK0009366932 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series BRF454EOA 41 with ISIN DK0009367070 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series 422.E.OA Cb3.ju27 RF with ISIN DK0009412207 has per 1 October 2026 and until and including 1 January 2027 been set at 2.91 % p.a.

Series G-422.E.OA Cb3.ju27 RF with ISIN DK0009412397 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series 422.B.OA Cb3.ju27 RF with ISIN DK0009412470 has per 1 October 2026 and until and including 1 January 2027 been set at 3.00 % p.a.

Series G422.E.OA Cb3.ju27 RF with ISIN DK0009414682 has per 1 October 2026 and until and including 1 January 2027 been set at 2.76 % p.a.

Series 422.E.OA Cb3.ju28 RF with ISIN DK0009414765 has per 1 October 2026 and until and including 1 January 2027 been set at 2.79 % p.a.

Series 422.E.OA Cb3.ju29 RF with ISIN DK0009417198 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series G422.E.OA Cb3 ju29 RF with ISIN DK0009417271 has per 1 October 2026 and until and including 1 January 2027 been set at 2.85 % p.a.

Series 422.E.OA Cb3.ju30 RF with ISIN DK0009419137 has per 1 October 2026 and until and including 1 January 2027 been set at 2.62 % p.a.

Series SNP322.ap.28 with ISIN DK0009417008 has per 1 October 2026 and until and including 1 January 2027 been set at 3.23 % p.a.

Questions may be addressed to Christian Bech-Ravn, tel. (+45) 89 89 92 25.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

CALGARY, Alberta, Sept. 29, 2026 (GLOBE NEWSWIRE) — Esker Infrastructure Corp. (formerly Cielo Waste Solutions Corp.) (TSXV: CMC; OTCQB: CWSFF) (“Esker” or the “Company”) is pleased to announce it has changed its name to Esker Infrastructure Corp. (“Esker”), effective September 25, 2026, marking the final step in a year-long strategic transformation from a technology developer into a project developer. The name change reflects the Company’s previously disclosed strategic direction and business activities — specifically, its deliberate shift away from developing proprietary technology and toward originating, structuring, and financing infrastructure projects built on proven, third-party technologies.

The TSX Venture Exchange (“TSXV”) has conditionally approved the Company’s name change. The Company expects its common shares to begin trading on the TSXV under the new name and ticker symbol “ESKR” and on the OTCQB under the ticker symbol “ESKRF” at the opening of trading on October 2, 2026. The Company’s new CUSIP number will be 29643A109 and its new ISIN will be CA29643A1093. The Company’s listed common share purchase warrants issued in July 2022 and expiring in July 2027 are expected to begin trading under the new symbol “ESKR.WT” also at the opening of trading on October 2, 2026. The warrants will have the new CUSIP number 29643A117 and ISIN CA29643A1176.

Why Esker

An esker is a ridge formed by water flowing beneath a glacier that creates a durable path through the landscape – a structure that outlasts the system that created it.

“Our new name reflects our strategy,” said Ryan C. Jackson, Chief Executive Officer. “We are a company that originates, structures and finances long-term, low-carbon energy infrastructure. We develop projects that are built to last.”

Esker’s Strategy

Over the past year, the Company has systematically repositioned its business model to focus on project origination and development rather than technology innovation. This transition has been supported by a renewed executive team and Board of Directors, a risk-gated framework for capital deployment, and a disciplined project development process designed to support sustainable, long-term growth. Together, these changes represent a comprehensive realignment of the Company’s strategy, governance and operational approach. The name change is the final chapter in that transition.

Esker’s inaugural project, Project Nahoonai, is expected to be executed in several phases across multiple sites in British Columbia, subject to meeting the criteria required to structure a financeable project at each site and is currently in a pre-final investment decision (“FID”) stage.

“The name change is a change in identity, not in direction,” added Mr. Jackson. “The strategy that has guided our recent executive and Board appointments — building the team and the platform needed to originate, structure and finance a pipeline of projects.”

No Action Required

The name change will not result in a change to the Company’s business, affairs or issued and outstanding share capital. Existing share certificates representing common shares of the Company are expected to remain valid and shareholders are not expected to be required to exchange their share certificates.  

Other than the change in the Company’s name and trading symbols described above, shareholders are not required to take any action as a result of the name change.

ABOUT ESKER

Esker Infrastructure Corp. (formerly Cielo Waste Solutions Corp.) is a project development company advancing sustainable aviation fuel and other low-carbon energy projects. Esker combines strategic feedstock partnerships with proven third-party technologies to develop a scalable pipeline of waste-to-fuels projects, anchored by its flagship Project Nahoonai in British Columbia.

For further information, please contact:
Esker Investor Relations
Ryan C. Jackson, Chief Executive Officer
Phone: (403) 348-2972
Email: investors@eskercorp.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain certain forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements regarding the approval of the TSXV, the anticipated commencement of trading of the Company’s common shares and share purchase warrants under its new name and trading symbols, the continued validity of existing share certificates and whether shareholders will be required to exchange their share certificates, the Company’s leadership team, the Company’s continued transition to, and implementation of, its business model as a project developer and low-carbon energy infrastructure platform, the Company’s business strategy, including the origination, structuring, financing and development of a portfolio of waste-to-fuels and other low-carbon energy projects, the development and execution of Project Nahoonai in multiple phases and across multiple sites in British Columbia; the satisfaction of the criteria required to structure a financeable project at each site; the advancement of multiple sites, sustainable, long-term growth, and the Company’s project pipeline.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors, many of which are beyond the control of the Company, that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Management to Discuss TruGolf’s Golf Technology Business and Proposed Acquisition of Polymath

SALT LAKE CITY, Utah, and TORONTO, Canada, Sept. 29, 2026 (GLOBE NEWSWIRE) — TruGolf Holdings, Inc. (NASDAQ: TRUG) (“TruGolf” or the “Company”) today announced that Brenner Adams, Chairman and Interim CEO of TruGolf, and Natalie Hirsch, Interim CEO and CFO of Polymath Research Inc. (“Polymath”), will present at The ThinkEquity Conference on Thursday, Oct. 15, 2026, at the Mandarin Oriental in New York.

Management will discuss TruGolf’s golf technology business, including the TruGolf Links franchise model, and the Company’s expansion into tokenized financial infrastructure through its acquisition of Polymath. Management will also hold one-on-one meetings with investors throughout the day.

“New York is the right room for this story,” said Natalie Hirsch. “We look forward to walking investors through how Polymath’s institutional tokenization infrastructure and TruGolf’s established golf technology business fit together, and where we’re taking the combined company.”

Investors interested in meeting with management may contact their ThinkEquity representative or ThinkEquity Corporate Access at corporateaccess@think-equity.com

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. These statements relate to future events, future expectations, plans and prospects. Although the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. “Risk Factors” in the Company’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

About TruGolf

Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf’s mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology – because TruGolf believes Golf is for Everyone. TruGolf’s team has built award-winning video games (“Links”), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6. Since TruGolf’s beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology.

About Polymath

Polymath is a privately held Canadian technology company that develops enterprise-grade capital markets infrastructure for the issuance, compliance, and lifecycle management of regulated digital securities and other tokenized financial instruments for private and institutional markets.

Investor Contact: Michael Bacal, mbacal@darrowir.com, 917-886-9071
Media Contact: David Cash, david.cash@polymath.network, +1 416 877 2562

Initial order potential first step to a multi-year deployment program.

GARDENA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Polar Power, Inc. (Nasdaq: POLA) (“Polar” or the “Company”), a designer and manufacturer of high-efficiency DC power systems for telecom and other mission-critical applications, today announced it has received a trial order for 50 propane-fueled DC generators from a major Tier 1 telecom operator in Southeast Asia. The generators will power off-grid and bad-grid cell sites.

The trial is the first phase of a potential five-year program that could cover approximately 2,500 of the customer’s sites. Discussions between the Company and this customer have begun on the next phase of 200 propane generators. The customer has not committed to broader deployment. If it proceeds, and based on current estimated system pricing, the opportunity could represent up to approximately $60 million in revenue over five years. Polar’s DC Generator ranges from $19,000 to $27,000 each depending on accessories and service options.

The order follows the Company’s more than five years of work with telecom operators in the Asia-Pacific region, including vendor qualification, multiple rounds of technical evaluation, field testing, and operational reviews.

According to the TowerXchange’s Q2 2024 Asia Guide there are 426,967 telecom towers/sites across the eight Southeast Asian markets.

“This order is an important step toward modernizing telecom power with LPG and DC systems,” said Arthur D. Sams, Chief Executive Officer of Polar. “We believe the combination of economic and environmental benefits will attract other operators and LPG distributors, whose participation could help accelerate our sales. Our expectation is that orders from other Telecom companies in this region will take months to close as opposed to years due to the large energy savings especially with the rising cost and theft of diesel fuel.”

Product and expected benefits

Polar’s DC generator combines its Supra^™ system controls and a high-efficiency permanent magnet alternator with Toyota 1KS prime power engines. Based on field experience, the Company estimates that:

• Fuel: The system uses approximately 40% less fuel than diesel AC generator solutions without solar. Paired with solar, savings have been demonstrated at 59% and higher.
• Maintenance: The oil change interval is approximately 4,500 hours, versus approximately 250 hours for standard diesel AC gensets, which reduces the cost of site visits.
• Operating cost: Because fuel is a large share of operating expense at off-grid and bad-grid sites, fuel savings has a meaningfully impact on lowering total site OPEX.

Supply readiness

Given long engine lead times, Polar has purchased approximately 2,000 Toyota 1KS engines to support potential volume growth. The Company previously wrote down approximately $4 million of usable engine inventory, and expects that using this inventory may support improved margins as volumes ramp. Polar’s large inventory of Toyota 1KS engines should help facilitate a rapid delivery of generators into emerging markets.

The economics is driving the sale

1. Fuel Savings. During the field trails Polar demonstrated 40% fuel savings. From field observation, diesel cost per site ranges from $960 to $2,400 per month. The estimated diesel cost does not include theft in the region of 15% to 25%. The net savings at 40% is $384 to $960 a month. Assuming a deployment of 2,500 sites, the annual saving ranges from $11M to $28M with Polar DC generators.
2. Maintenance savings. Scheduled maintenance service for a Diesel AC generator is 200 to 250 hours; so, running 12 to 24 hours a day will require 18 to 36 service trips a year. The Polar DC generator with the Toyota engine has a scheduled service maintenance of 4,500 hours requiring a maximum of 2 visits a year running 24 hours a year. The Company estimates that the cost is $100 to $150 per site visit for a Diesel AC generator, totaling between $1,800 to $5,400 per year per site, while maintaining a Polar DC generator costs $600 per year running 24/7. Assuming a deployment of 2,500 sites, the annual saving ranges from $3M to $12M with Polar DC generator.

Broader LPG opportunity

In addition, a major local LPG distributor expects to receive a contract from its customer to fuel each site for 6 years. Our telecom customer was concerned with getting propane to each site and the participation of a major LPG distributor was essential to the program success. The LPG distributor will benefit with a substantial increase in revenues as new wave of opportunity opens with power generation using LPG in place of diesel.

About Polar Power, Inc.

Polar Power, Inc. (NASDAQ: POLA) designs, manufactures and sells direct-current power generators, renewable energy systems and other power solutions for applications including telecommunications, drone defense, robotics, EV charging, micro-grids military and commercial markets. The Company is headquartered in Gardena, California.

For more information, please visit www.polarpower.com. or follow Polar Power on www.linkedin.com/company/polar-power-inc/.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the potential size, timing, and revenue of a broader deployment, customer adoption, expected fuel and cost savings, LPG distributor participation, and future margins. These statements involve risks and uncertainties, including but not limited to that the customer may not proceed beyond the trial, delays in telecom adoption cycles, pricing and competition, supply chain and inventory risks, and other factors described in the Company’s SEC filings, including its most recent Form 10-K and 10-Q. Actual results may differ materially. The Company undertakes no obligation to update these statements except as required by law.

Media and Investor Relations
Polar Power, Inc.
249 E. Gardena Blvd.
Gardena, CA 90248
Tel: 310-830-9153
Email: ir@polarpowerinc.com
www.polarpower.com

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~ 

~ Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anchor for the submitted BLA and the confirmatory study; the new analysis demonstrated 80% slowing of disease progression based on cUHDRS (nominal p=0.005) and 67% based on TFC (nominal p=0.011) ~ 

 ~ Treatment effect at 48 months likely understated by substantial missing data and survivor bias in updated external control; post hoc analysis using prior external control showed slowing of disease of 54% on cUHDRS (nominal p=0.041) and 68% on TFC (nominal p=0.001) at 48 months ~

~ These positive data are meaningful for Huntington’s disease patients who currently have no approved disease-modifying treatment options ~

~ Investor conference call and webcast today at 8:30 a.m. ET ~

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

“Four years after a single administration, ifezuntirgene inilparvovec continues to show meaningful slowing of disease progression, further strengthening our conviction in its benefit for people living with Huntington’s disease,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “At 48 months, Total Functional Capacity (TFC), the primary measure of our confirmatory study, demonstrated consistent slowing of functional decline, with the absolute treatment benefit maintained in Month 48. Furthermore, the observed differences between the high and low doses on both composite Unified Huntington’s Disease Rating Scale (cUHDRS) and TFC are consistent with a dose-dependent treatment effect. The updated 36-month analysis, which now includes three additional high-dose patients, showed a substantial effect on cUHDRS and TFC, further reinforcing the data included in our license applications. We believe these data are clinically meaningful for Huntington’s disease patients, and we look forward to presenting them at a future scientific meeting.”

Topline Clinical Data at 36 months and 48 months¹

Today’s announcement comprises results from the ongoing Phase I/II studies at two timepoints, with a data cutoff of June 30, 2026. Twenty-nine patients have been treated with ifezuntirgene inilparvovec (n=17 high dose; n=12 low dose) across the studies’ first two cohorts. The new 36-month analysis now includes 15 high-dose and 12 low-dose patients, with three additional high-dose patients having reached that timepoint since the September 2025 analysis. The 48-month analysis includes 12 patients at each dose.

Outcomes for the 36-month and 48-month analyses were compared to propensity score-matched external controls (n=1,337 for high dose) from an updated ENROLL-HD natural history dataset with a September 2025 cutoff. As is common with longitudinal natural history studies, missingness of data increased with duration of follow-up, reaching 53% in the updated ENROLL-HD matched controls at 48 months. The Company’s analysis of the updated control showed that patients discontinuing follow-up were progressing materially faster than those remaining in the control group. The Company believes these factors likely understated disease progression in the control and the resulting treatment effect of ifezuntirgene inilparvovec at 48 months.

At the June 2026 Type B meeting, the FDA communicated that the 36-month data from 12 high-dose patients would be acceptable as the primary basis for the BLA submission under the accelerated approval pathway, and the submission was made accordingly. The BLA submission of ifezuntirgene inilparvovec predated the topline results announced today and these results were not part of the submission.

High-Dose Results at 36 Months (n=15)

• cUHDRS showed 80% slowing of disease progression compared to the updated external control (nominal p=0.005). Treated patients had a mean change in cUHDRS from baseline of -0.28 compared to a change of -1.39 for the external control, a favorable treatment difference of 1.12 compared to baseline.

• TFC showed 67% slowing of disease progression compared to the updated external control (nominal p=0.011). Treated patients had a mean change in TFC from baseline of -0.27 compared to a change of -0.82 for patients in the propensity score-matched external control, a favorable treatment difference of 0.55 compared to baseline.
• Mean cerebrospinal neurofilament light protein (CSF NfL) was 6% below baseline (n=14).

High-Dose Results at 48 Months (n=12)

• cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Treated patients had a mean change in cUHDRS from baseline of -0.90 compared to a change of -1.61 for the external control, a favorable treatment difference of 0.71 compared to baseline.
• TFC showed 61% slowing of disease progression compared to the updated external control (nominal p=0.008). Treated patients had a mean change in TFC from baseline of -0.37 compared to a change of -0.94 for the external control, a favorable treatment difference of 0.57 compared to baseline.
• In a post-hoc sensitivity analysis using the prior ENROLL-HD external control, the 48-month analysis showed 53.5% slowing based on cUHDRS (nominal p=0.041) and 68.3% based on TFC (nominal p=0.001).
• Mean cerebrospinal neurofilament light protein (CSF NfL) was 4% above baseline (n=11).

Dose Comparison at 48 Months (high dose n=12, low dose n=12)

• The observed differences between the high and low doses are consistent with a dose-dependent treatment effect. At 48 months, mean change from baseline in cUHDRS was –0.91 in high-dose patients compared with −1.94 in low-dose patients, a difference of 1.03 in favor of the high dose. Mean change from baseline in TFC was −0.30 in high-dose patients compared with −0.70 in low-dose patients, a difference of 0.40 in favor of the high dose.

“Huntington’s disease does not slow on its own; the biology is one of inevitable progressive decline,” stated Victor Sung, M.D., professor of neurology at the University of Alabama at Birmingham (UAB), director of the UAB Huntington’s Disease Clinic. “What I find particularly notable in the expanded data is the consistently meaningful treatment effect at 36 months, and the apparent stability of the functional capacity benefit through Month 48. We see this even as the rate of decline in the updated comparator dataset slowed, an anticipated shift which appears to reflect some attrition in the longitudinal external control data, and which does not reflect the typical clinical presentation of accelerating decline over time. Total Functional Capacity tracks things that matter the most to patients and families – ability to work, perform household chores and handle daily self-care activities. Seeing that treatment difference maintained at four years is meaningful for people living with this relentlessly progressive degenerative disease.”

Ifezuntirgene inilparvovec continues to be generally well-tolerated, with a manageable safety profile at both doses. The most common adverse events in the treatment groups were related to the administration procedure, and all have resolved. As previously disclosed, five high dose participants (17%) experienced a treatment-related serious adverse event (SAE) related to central nervous system inflammation, all of which fully resolved.

Since the September 2025 data readout, one suicide in a low-dose patient occurred, approximately five years after receiving treatment. This was assessed as unrelated to treatment by the study investigator. Suicidal ideation and completed suicide occur at substantially elevated rates in Huntington’s disease relative to the general population, and suicide is among the leading causes of death in those with the disease.

Investor Conference Call and Webcast Information 

uniQure management will host an investor conference call and webcast today, Tuesday, September 29 at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About Ifezuntirgene Inilparvovec (AMT-130)

Ifezuntirgene inilparvovec is a novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes a proprietary, gene-silencing miQURE^® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.

About the Phase I/II Clinical Program of Ifezuntirgene Inilparvovec

uniQure is conducting two multi-center Phase I/II clinical studies evaluating the safety, tolerability, and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

In total, the Phase I/II clinical studies have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients who received either a single administration of ifezuntirgene inilparvovec (n=6 low dose; n=10 high dose) or a sham procedure (n=10); four control patients subsequently crossed over to treatment after approximately 12 months. The European open-label study enrolled 13 patients (n=6 low dose; n=7 high dose). A third cohort of 12 patients explored both doses in combination with immunosuppression, and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.

Additional details are available on www.clinicaltrials.gov (NCT05243017, NCT04120493)

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Approximately 75,000 people have Huntington’s disease in the U.S.², EU³, and the UK⁴, with hundreds of thousands of others at risk of inheriting the disease. Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “establish,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and similar expressions and the negatives of those terms. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s beliefs related to the factors that likely understate disease progression in the updated ENROLL-HD controls and the Company’s belief that ifezuntirgene inilparvovec meaningfully reduces disease progression based on its evaluation and view of certain measurements of disease progression. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks related to the Company’s Phase I/II clinical trials of ifezuntirgene inilparvovec, including the risk that such trials will be unable to continue to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that the FDA ultimately concludes that the Phase I/II trial data are not sufficient to support a BLA or accelerated approval; the risk that more patient data become available that results in a different interpretation than the one derived from the year three and four data analyses, respectively; risks related to the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to commercialize ifezuntirgene inilparvovec, if approved; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the continued development and acceptance of gene therapies; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed and on acceptable terms. These risks and uncertainties are more fully described under the heading “Risk Factors” in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC“), including its Annual Report on Form 10-K filed with the SEC on March 2, 2026, its Quarterly Report on Forms 10-Q filed with the SEC on May 5, 2026 and July 29, 2026, respectively, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:
FOR INVESTORS:	FOR MEDIA:
Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com	Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com

¹ cUHDRS is the pre-specified primary endpoint for the 48 months analysis; all other p-values are nominal. The 36-month data included 15 high-dose patients; the 48-month analysis included 12 high-dose patients. Percentage slowing was sensitive to the magnitude of decline in the external control.
² Yohrling G, et al. Neurology 2020;94(15 Suppl):954.
³ Medina A, et al. Mov Disord 2022;37(12):2327–2335
⁴ Furby H, et al. Eur J Neurol 2022;29(8):2249–2257.

Milestone Marks Recombinant Spider Silk’s Move from Scaled Production to a First-of-Its-Kind Performance Textile

ANN ARBOR, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the shipment of its first commercial order of recombinant spider silk yarn. The custom-engineered yarn was produced to fulfill a purchase commitment from a globally recognized performance sports brand and is slated for development into a first-of-its-kind performance textile.

This spider silk sale is part of a confidential pilot development program. The program targets one of the most demanding and innovation-focused segments of the athletic apparel market. The yarn has been custom processed to the customer’s specifications and has now shipped.

“Completing the delivery of this spider silk yarn is a huge milestone for Kraig Labs,” said Kim Thompson, Founder and CEO of Kraig Labs. “The volume is small by design. This is a precision application, not a bulk order. It is exactly the kind of application where spider silk’s real advantages can be highlighted. Strength, flexibility, toughness, and light weight, under conditions pushing materials to their limits. This application is a shining example of how spider silk can transform markets.”

The shipment comes at a pivotal moment for the global textile industry, as fashion and performance brands explore new materials while confronting the challenge of moving promising fiber technologies from laboratory innovation to reliable production. Textile Exchange’s Materials Market Report 2026, published September 22, reported that global fiber production reached a record 139 million metric tons in 2025, with polyester accounting for 59% of total output and 88% of polyester production coming from virgin fossil-based sources. Against that backdrop, the opportunity for emerging performance materials is significant, but so is the challenge: new fibers must deliver differentiated properties while proving they can be produced consistently and integrated into an industry built around enormous volumes of established materials. Kraig Labs’ first commercial shipment represents an important step from material innovation and scaled production toward real-world textile adoption.

Kraig Labs views elite performance apparel as one of the clearest proving grounds for recombinant spider silk. A category where gains in strength-to-weight ratio and durability translate directly into competitive advantage for the athlete.

“High-performance sport is where materials prove themselves,” Thompson continued. “Performance wins. That is the only thing that matters in elite sport. It’s about how it performs when everything is on the line, and that’s exactly what we intend to prove.”

While the quantity of silk in this shipment is small, Kraig Labs believes the true significance lies in what it represents for the broader athletic and performance textile market. A successful application here demonstrates that recombinant spider silk can meet the exacting technical standards of elite sport, standards few materials, natural or synthetic, are able to satisfy. A validated performance application of this kind opens the door to further engagement with brands across the performance apparel space.

“This is the kind of project that changes the conversation,” Thompson concluded. “When a brand at this level puts our material to the test, the results speak for themselves. We intend for this to be the first of many.”

The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/656da44f-ba1b-467d-81d2-63af7e1d4a8e

https://www.globenewswire.com/NewsRoom/AttachmentNg/8621458d-87fb-47e9-b5e1-aaa6490608da 

• Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor 
• The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor
• Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months from resubmission
• Current cash position allows runway into 2H 2027

MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA within 30 days and a new assigned PDUFA date to be six months from the date of resubmission.

The NDA resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status, the highest FDA inspection classification indicating that a facility is in an acceptable state of current Good Manufacturing Practices (cGMP) compliance. The new vendor’s CMC data package includes technical specifications similar to the original third-party manufacturing vendor, and the new vendor has already produced OLC drug product and completed 12-month stability studies. In addition, the Company has provided additional in-vitro bridging data between the two vendors as recommended by the FDA in previous discussions.

In June 2026, the Company received a Complete Response Letter (CRL) from the FDA regarding the first OLC NDA resubmission. The 2026 CRL cited the same third-party manufacturing deficiencies identified in a previous CRL issued in June 2025 to the initial NDA submission, as a result of the FDA not having conducted the reinspection of the original third-party manufacturing vendor. The FDA did not raise concerns regarding clinical efficacy or safety data and did not request additional data from the Company. The Company’s original third-party manufacturing vendor has received written notification from the FDA that its facility inspection has been assigned, but the inspection has not yet occurred as of September 29, 2026. If the original third-party manufacturing vendor is inspected in the near term and deemed cGMP-compliant, the Company plans to seek FDA alignment on a shorter approval timeline for the OLC NDA resubmission. Unicycive intends to keep both drug product vendors to maintain supply chain redundancy.

“We believe this resubmission reflects an efficient path to potential approval and, if approved, a potentially faster path to bringing OLC to patients who need additional treatment options,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “By adding an alternative primary manufacturing vendor, we are positioning the NDA for expedient review and potential approval. If the FDA’s assigned inspection of the original vendor is completed favorably in the interim, that outcome could provide a potential timing benefit. We continue to advance commercial readiness activities in anticipation of a potential launch, with the goal of helping patients with CKD on dialysis who continue to struggle with hyperphosphatemia.”

The NDA is supported by data from three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis, along with multiple preclinical studies and CMC data.

As of June 30, 2026, unaudited cash, cash equivalents and marketable securities totaled $61.4 million, supporting continued OLC commercial launch preparation and an expected cash runway into the second half of 2027.

About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.¹ Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

¹Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of our NDA; the risk that the original third-party manufacturing vendor’s reinspection may not occur within a timeframe that benefits our regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Unicycive Therapeutics
media@unicycive.com 

SOURCE: Unicycive Therapeutics, Inc.